Crucially, the TIMP1 inhibitor FXR agonist 3 suppressed MSCs-driven BC proliferation <i>in vitro</i> and attenuated tumor growth in PDX models by disrupting the cMet-RAP1 signaling pathway without systemic toxicity. Here, MET is linked to breast cancer.